Aurobindo Pharma Signs Royalty-Free License with MSD for Generic Alimatravir Supply

Aurobindo Pharma Limited has entered into a non-exclusive voluntary licensing agreement with MSD (Merck & Co., Inc.) for alimatravir, an HIV prevention medication. This agreement is royalty-free and aims to facilitate the supply of generic alimatravir to 129 Low- & Middle-Income Countries (LMICs), subject to regulatory approvals. The collaboration is intended to expand access to potential new therapies for HIV prevention globally.

Key highlights

• Aurobindo Pharma secured a non-exclusive voluntary license from MSD.
• The agreement is royalty-free, covering generic alimatravir.
• Supply is intended for 129 Low- & Middle-Income Countries (LMICs).
• The medication is targeted for HIV prevention efforts.
• The agreement was signed before the completion of Phase 3 trial enrollment for alimatravir.

What drove it

Aurobindo Pharma stated that expanding access to high-quality, affordable medicines remains central to its purpose. The company indicated that this collaboration with MSD reflects its continued commitment to partnering with innovators to accelerate equitable access to potential new therapies.

Why it matters

This agreement positions Aurobindo Pharma as a key manufacturer enabling broader access to a potential HIV prevention drug in regions most affected by new diagnoses. By securing the license before Phase 3 trial completion, the initiative aims to enable early scale-up and planning for global supply, pending successful development and regulatory approvals. This move aligns with public health goals to strengthen HIV prevention efforts in underserved countries, leveraging Aurobindo Pharma's manufacturing capabilities.

What to watch

Further developments will involve the progress of alimatravir's Phase 3 trials and subsequent regulatory approvals in the designated LMICs. The market will observe Aurobindo Pharma's subsequent manufacturing and supply rollout in these regions.